Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Oxford
Headquarters: Oxford, United Kingdom
Website: http://www.ox.ac.uk
Year Founded: N/A
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 26, 2024
Politics, Policy & Law
Marty Makary’s turn in the spotlight
Trump’s FDA commissioner pick has complex, controversial history
BioCentury | Nov 21, 2024
Management Tracks
Boshoff to succeed Dolsten as Pfizer CSO
Plus: Hwang joins Metaphore, Flagship and updates from FDA, MHRA, ArrePath, ABT, Unnatural, Thryv and more
BioCentury | Oct 15, 2024
Management Tracks
Rubin leaving Boundless as CFO, new CSOs for C4, Avacta and Commit
Plus: David Cameron named chair of Oxford-Harrington Rare Disease Centre’s advisory council, and updates from Twist, Boundless, Lucy and more
BioCentury | Jul 25, 2024
Discovery & Translation
Science Spotlight: Delivering full-length dystrophin, intracellular bioPROTACs, and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 12, 2024
Finance
Venture Report: With more company creation on tap, Flagship raises $3.6B
Plus: Big rounds for Element, Beacon and Myricx
BioCentury | Jul 10, 2024
Emerging Company Profile
Mestag: Attacking tumors from within
Immunology company’s lead program targets a specific fibroblast subpopulation to induce formation of tertiary lymphoid structures in solid tumors
BioCentury | Jun 21, 2024
Finance
Venture Report: Syncona’s backs a pair of biotechs; Marea makes debut with $190M
Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability
BioCentury | Apr 25, 2024
Management Tracks
Smart to lead Actym as CEO
Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotech
Items per page:
1 - 10 of 602